Why Recursion Pharmaceuticals matters
Recursion reported Q1 2026 revenue of $6.5 million and a net loss of $117.5 million on May 6, 2026, with five clinical programs advancing. In its Q2 report on August 5, 2026 it cut 2026 cash operating expense guidance to $375 million, held $557 million in cash, and said Genentech optioned the first neuroscience target from their collaboration. Partnerships with Roche/Genentech and Sanofi have paid more than $500 million to date.
The numberCut 2026 cash operating expense guidance to $375M in Aug 2026, nearly 40% below 2024, with runway into early 2028
On The All Things AI 100
Listed under Vertical AI and science. AI built for one field: law, medicine, drug discovery, finance.
Quick answers
- What does Recursion Pharmaceuticals do?
- Clinical-stage biotech using automated labs and AI (Recursion OS) to discover and develop drugs. Recursion reported Q1 2026 revenue of $6.5 million and a net loss of $117.5 million on May 6, 2026, with five clinical programs advancing.
- What AI capabilities does Recursion Pharmaceuticals offer?
- Recursion Pharmaceuticals offers Recursion OS, an AI and automated laboratory system used to generate and analyze biological data for drug discovery. Machine learning models study cell images and related experiments to map disease biology, rank targets, and help select or design compounds. Research partners and internal teams use those results to move therapeutic candidates forward.
- Why is Recursion Pharmaceuticals on The All Things AI 100?
- Recursion Pharmaceuticals is listed under Vertical AI and science. AI built for one field: law, medicine, drug discovery, finance. Cut 2026 cash operating expense guidance to $375M in Aug 2026, nearly 40% below 2024, with runway into early 2028.
- Where is Recursion Pharmaceuticals based, and who owns it?
- Recursion Pharmaceuticals is based in Salt Lake City, UT, was founded in 2013 and is public (NASDAQ: RXRX).